Logo

ChondroGene Raises $500,000 in Private Placement

Sep 13, 2004

NEW YORK, Sept. 13 (GenomeWeb News) - ChondroGene of Toronto has raised $500,000 in a private placement in Canada, bringing the total of this financing round to $5.5 million, the company said today.

 

Last month, ChondroGene raised $5 million in a private placement in the US under the same terms, $.95 per common share.

 

The funding will provide the company with operating capital into 2006. ChondroGene, which develops disease-specific biomarkers, plans to advance its technology into areas outside of osteoarthritis, such as cancer and neurological disorders.

Breaking News
The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.